STAAR Surgical Co. Files Proxy Statement Supplement

TL;DR

STAAR Surgical filed a proxy update, check the latest docs before voting.

AI Summary

STAAR Surgical Company filed a supplemental proxy statement on October 30, 2025, to its original proxy statement dated September 16, 2025. This filing is related to the company's proxy materials and does not require a filing fee.

Why It Matters

This filing provides updated information to shareholders regarding matters to be voted on at the company's upcoming meeting, impacting their ability to make informed decisions.

Risk Assessment

Risk Level: low — This is a routine administrative filing related to proxy statements and does not indicate any immediate financial or operational risks.

Key Players & Entities

• STAAR SURGICAL CO (company) — Filer of the proxy statement
• October 30, 2025 (date) — Date of the supplemental filing
• September 16, 2025 (date) — Date of the original proxy statement

FAQ

Key Financial Figures

• $28.00 — k held immediately prior to the Merger, $28.00 in cash, without interest and subject t

Filing Documents

• d103774ddefa14a.htm (DEFA14A) — 239KB
• g103774dsp1a.jpg (GRAPHIC) — 4KB
• g103774dsp1b.jpg (GRAPHIC) — 9KB
• g103774dsp1c.jpg (GRAPHIC) — 1KB
• g103774g04v01.jpg (GRAPHIC) — 17KB
• g103774g1030011908714.jpg (GRAPHIC) — 3KB
• 0001193125-25-258558.txt ( ) — 288KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 SUPPLEMENT DATED OCTOBER 30, 2025, TO PROXY STATEMENT DATED SEPTEMBER 16, 2025 This document is a supplement dated October 30, 2025 (this "Supplement") to the proxy statement dated September 16, 2025, and first mailed to stockholders of STAAR Surgical Company ("STAAR" or the "Company") on or about September 16, 2025, which is referred to herein as the "proxy statement". This Supplement amends and restates an earlier supplement dated October 13, 2025 (which was filed by STAAR on Form 8-K with the U.S. Securities and Exchange Commission (the "SEC") on October 14, 2025, under the caption "Supplement to the Proxy Statement"). INTRODUCTION AND EXPLANATORY NOTE Capitalized terms used herein, but not otherwise defined, shall have the meanings ascribed to such terms in the proxy statement. Except as described in this Supplement, the information provided in the proxy statement relating to the Merger Agreement and the transactions contemplated thereby continue to apply. This Supplement and the documents referred to in this Supplement should be read in conjunction with the proxy statement, the annexes and exhibits to the proxy statement and the documents referred to in the proxy statement, each of which should be read in its entirety. All page references herein are to pages in the proxy proxy statement. For clarity, new text within restated paragraphs from the proxy statement (excluding the notice of the Special Meeting) is highlighted with bold, underlined text , while deleted text is bold and stricken-through . As previously disclosed, on August 4, 2025, STAAR entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement") with Alcon Research, LLC, a Delaware limited liability company ("Alcon"), and Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of Alcon ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into STAAR (the "Merger"), with STAAR surviving the Merger as a wholly owned subsidiary of Alcon. If the Merger is completed, STAAR stockholders will receive, in exchange for each share of STAAR common stock held immediately prior to the Merger, $28.00 in cash, without interest and subject to any applicable tax withholding. The STAAR Board of Directors (the "Board") has unanimously approved the Merger Agreement and has recommended that STAAR stockholders vote in favor of adopting the Merger Agreement. The transaction price represents an approximately 59% premium to the 90-day volume weighted average price of STAAR common stock on August 4, 2025, the last trading day before the public announcement of the execution of the Merger Agreement, and an approximately 51% premium to the closing price of STAAR common stock on August 4, 2025. The common stock of STAAR is listed on NASDAQ under the symbol "STAA." Following the consummation of the Merger, STAAR common stock will no longer be listed on any stock exchange or quotation system, and STAAR will cease to be a publicly traded company. The Merger cannot be completed without approval of the proposal to adopt the Merger Agreement by the affirmative vote of holders of a majority of the outstanding shares of STAAR common stock entitled to vote thereon . Because of this, STAAR is holding a special meeting of its stockholders (the "Special Meeting") to vote on the proposal necessary to consummate the Merger (the "Merger Proposal"). As disclosed by STAAR on a Current Report on Form 8-K filed on October 27, 2025, STAAR announced that, in light of ongoing discussions with Alcon, the Special Meeting, which had previously been adjourned to November 6, 2025 at 8:30 a.m. Pacific Time, has been postponed to December 3, 2025 at 8:30 a.m. Pacific Time. The record date for the Special Meeting, which was previously September 12, 2024, has been reset to be the close of business on October 24, 2025 (the "Record Date"). Stockholders who hold shares as of the Record Date will be eligible to vote at the postponed Special Meeting on December 3, 2025. The Special Meeting will be held in a virt

View Full Filing

View this DEFA14A filing on SEC EDGAR